News | March 20, 2012

Blue Medical Launches Drug-Eluting Balloon, Stent on a DEB

March 20, 2012 - MarBlue Medical announced the global product launch of its CE-marked drug-eluting balloon (DEB) Protege as well as its Pioneer cobalt chrome (CoCr) stent on a DEB. The full market launch of the new DEB technology is a major step forward in Blue Medical's quest to improve the quality of life of patients with cardiovascular diseases, while at the same time reducing procedure costs.

Blue Medical's DEB therapy delivers a controlled dose of paclitaxel to the coronary artery during balloon angioplasty. The combined device with a coronary stent, the DEB offers a one-time shot of the drug, instead of continuous drug delivery from a drug-eluting stent. This significantly reduces the period in which antiplatelet medication could be required. Low major adverse cardiovascular events (MACE) rates and low late lumen loss indicating the efficacy and safety of the Protege and Pioneer DEB products are confirmed by the clinical data of Blue Medical's PIONEER human trial.

"Increased late stent thrombosis risk and the long-term dual antiplatelet medication which are associated with the majority of current drug-eluting stents is a concern in treating our patients today," said primary investigator of the PIONEER study Peter Smits, M.D., head of interventional cardiology at the Maasstad Hospital, Rotterdam, The Netherlands. "DEB therapy in combination with bare metal coronary stents offers a potential solution for reducing late lumen loss without the need for long-term dual-antiplatelet medication, improving patient comfort and reducing risks for bleeding and stent thrombosis."

"Our extensive research effort combined with human evaluation ensures a highly reliable science-based and effective DEB technology," said Ronald Horvers, CEO of Blue Medical. "The critical and extensive review of the Dutch Medicine Evaluation Board and notified body BSI enables us to provide an attractive alternative for treating coronary disease."

For more information: www.bluemedical.com

Related Content

Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Medtronic Announces Japanese Regulatory Approval for In.Pact Admiral Drug-Coated Balloon
News | Drug-Eluting Balloons| September 13, 2017
Medtronic plc announced that the In.Pact Admiral Drug-Coated Balloon (DCB) received approval from the Japanese Ministry...
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Lutonix 035 Drug Coated Balloon Earns Additional FDA Premarket Approval
Technology | Drug-Eluting Balloons| August 29, 2017
C.R. Bard Inc. announced the Lutonix 035 Drug Coated Balloon PTA Catheter (DCB) has been granted premarket approval (...
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
Spectranetics Announces FDA Approval of Stellarex Drug-Coated Balloon
Technology | Drug-Eluting Balloons| July 26, 2017
The Spectranetics Corp. announced receipt of U.S. Food and Drug Administration (FDA) pre-market approval (PMA) of the...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Overlay Init